Deutsche Bank
NKTR icon

Deutsche Bank’s Nektar Therapeutics NKTR Stock Holding History

Deutsche Bank’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.6M Buy
91,671
+928
+1% +$52.8K ﹤0.01% 1186
2025
Q4 		$3.84M Buy
90,743
+743
+0.8% +$41.6K ﹤0.01% 1439
2025
Q3 		$5.12M Buy
+90,000
New +$2.98M ﹤0.01% 1296
2025
Q2 		– Sell
-5,903
Closed -$60.2K – 3686
2025
Q1 		$60.2K Hold
5,903
– – ﹤0.01% 3342
2024
Q4 		$82.4K Hold
5,903
– – ﹤0.01% 3336
2024
Q3 		$115K Buy
+5,903
New +$113K ﹤0.01% 3170
2023
Q2 		– Sell
-8,647
Closed -$91.2K – 3878
2023
Q1 		$91.2K Buy
8,647
+2,163
+33% +$65.4K ﹤0.01% 3371
2022
Q4 		$220K Buy
6,484
+1,023
+19% +$49.5K ﹤0.01% 2929
2022
Q3 		$262K Sell
5,461
-6,008
-52% -$357K ﹤0.01% 2775
2022
Q2 		$653K Buy
11,469
+7,520
+190% +$474K ﹤0.01% 2433
2022
Q1 		$320K Sell
3,949
-12
-0.3% -$1.78K ﹤0.01% 3014
2021
Q4 		$803K Sell
3,961
-266
-6% -$57.7K ﹤0.01% 2567
2021
Q3 		$1.14M Buy
4,227
+3,132
+286% +$753K ﹤0.01% 2526
2021
Q2 		$281K Sell
1,095
-728
-40% -$201K ﹤0.01% 3585
2021
Q1 		$547K Buy
1,823
+856
+89% +$266K ﹤0.01% 3040
2020
Q4 		$246K Sell
967
-4,092
-81% -$1.06M ﹤0.01% 3355
2020
Q3 		$1.26M Buy
5,059
+2,871
+131% +$903K ﹤0.01% 2040
2020
Q2 		$760K Sell
2,188
-22,077
-91% -$6.89M ﹤0.01% 2389
2020
Q1 		$6.5M Sell
24,265
-18,560
-43% -$5.74M 0.01% 1112
2019
Q4 		$13.9M Sell
42,825
-26,932
-39% -$7.81M 0.01% 933
2019
Q3 		$19.1M Sell
69,757
-14,361
-17% -$5.27M 0.01% 799
2019
Q2 		$44.9M Buy
84,118
+48,434
+136% +$24.3M 0.03% 612
2019
Q1 		$18M Sell
35,684
-27,450
-43% -$16.3M 0.01% 1046
2018
Q4 		$31.1M Buy
63,134
+23,779
+60% +$14.4M 0.02% 680
2018
Q3 		$36M Buy
39,355
+3,421
+10% +$2.92M 0.02% 811
2018
Q2 		$26.3M Sell
35,934
-2,400
-6% -$2.77M 0.01% 1008
2018
Q1 		$61.1M Buy
38,334
+13,667
+55% +$17.6M 0.03% 561
2017
Q4 		$22.1M Sell
24,667
-59,686
-71% -$35.3M 0.01% 946
2017
Q3 		$30.4M Buy
84,353
+49,797
+144% +$15.6M 0.02% 780
2017
Q2 		$10.1M Buy
34,556
+23,406
+210% +$6.76M 0.01% 1394
2017
Q1 		$3.92M Sell
11,150
-27,000
-71% -$6.07M ﹤0.01% 1815
2016
Q4 		$7.02M Buy
38,150
+16,761
+78% +$3.41M 0.01% 1466
2016
Q3 		$5.51M Sell
21,389
-22,282
-51% -$5.74M ﹤0.01% 1668
2016
Q2 		$9.32M Sell
43,671
-14,239
-25% -$3.18M 0.01% 1349
2016
Q1 		$11.9M Sell
57,910
-12,216
-17% -$2.35M 0.01% 1157
2015
Q4 		$17.7M Buy
70,126
+50,720
+261% +$10.4M 0.01% 985
2015
Q3 		$3.19M Sell
19,406
-283
-1% -$50.1K ﹤0.01% 2137
2015
Q2 		$3.69M Sell
19,689
-9,639
-33% -$1.66M ﹤0.01% 2013
2015
Q1 		$4.84M Buy
29,328
+4,793
+20% +$985K ﹤0.01% 1808
2014
Q4 		$5.7M Buy
24,535
+6,601
+37% +$1.41M ﹤0.01% 1853
2014
Q3 		$3.25M Sell
17,934
-1,593
-8% -$305K ﹤0.01% 2146
2014
Q2 		$3.75M Sell
19,527
-6,425
-25% -$1.14M ﹤0.01% 2026
2014
Q1 		$4.72M Buy
25,952
+3,110
+14% +$615K ﹤0.01% 1849
2013
Q4 		$3.89M Sell
22,842
-14,512
-39% -$2.34M ﹤0.01% 1907
2013
Q3 		$5.85M Buy
37,354
+5,433
+17% +$1M ﹤0.01% 1709
2013
Q2 		$5.53M Buy
+31,921
New +$4.9M ﹤0.01% 1562

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deutsche Bank's NKTR Position: Q1 2026 in Review

Deutsche Bank increased its Nektar Therapeutics (NKTR) stake by 1% in Q1 2026, buying an estimated $52.8K and bringing the position to 91,671 shares worth $6.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1186.

Deutsche Bank first reported a position in NKTR in Q2 2013 and has held it in 46 quarters since. The position peaked at $61.1M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Deutsche Bank held 91,671 shares of Nektar Therapeutics worth $6.6M as of Q1 2026.
  • Deutsche Bank bought 928 Nektar Therapeutics shares in Q1 2026, an estimated $52.8K.
  • Nektar Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1186 holding.
  • Deutsche Bank first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • Deutsche Bank's Nektar Therapeutics position peaked at $61.1M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.